A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma von Kaufman, Jonathan L., Flowers, Christopher R., Rados, Karen D., Calandra, Gary B., Vose, Julie M., Hewes, L. Becker, Lonial, Sagar, Langston, Amelia A., Khoury, H. Jean, Lechowicz, Mary Jo, Waller, Edmund K.

Volltext

Anti-CD137 antibodies in the treatment of autoimmune disease and cancer von Mittler, Robert S, Foell, Juergen, McCausland, Megan, Strahotin, Simona, Niu, Liguo, Bapat, Abhijit, Hewes, L Becker

Volltext

PHOSPHORUS NMR SPECTROSCOPY OF EOSINOPHILIA MYALGIA SYNDROME (EMS) von Rajan, Sunder S., Hewes, L. Becker, Nelson, M. C., Clauw, Daniel J.

Volltext

Rationale for anti-GITR cancer immunotherapy von Knee, Deborah A, Hewes, Becker, Brogdon, Jennifer L

Volltext

Abstract 3516: AZD1208 PIM kinase inhibitor - Preliminary evidence of target pathway inhibition in Phase I clinical trials of AML von McEachern, Kristen A., Cao, Yichen, DuPont, Rachel, Pablo, Lourdes, McCoon, Patricia, Cortes, Jorge E., DeAngelo, Daniel J., Minden, Mark D., Hewes, Becker, Brown, Jeffrey L., Barrett, Carl

Volltext

Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I St... von Uy, Geoffrey L., Avigan, David, Cortes, Jorge E., Becker, Pamela S., Chen, Robert W., Liesveld, Jane L., Hewes, Becker, Johns, Don, Erba, Harry Paul

Volltext